Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation
Citations Over TimeTop 1% of 2022 papers
Abstract
Sclerostin negatively regulates bone formation by antagonizing Wnt signalling. An antibody targeting sclerostin for the treatment of postmenopausal osteoporosis was approved by the U.S. Food and Drug Administration, with a boxed warning for cardiovascular risk. Here we demonstrate that sclerostin participates in protecting cardiovascular system and inhibiting bone formation via different loops. Loop3 deficiency by genetic truncation could maintain sclerostin's protective effect on the cardiovascular system while attenuating its inhibitory effect on bone formation. We identify an aptamer, named aptscl56, which specifically targets sclerostin loop3 and use a modified aptscl56 version, called Apc001PE, as specific in vivo pharmacologic tool to validate the above effect of loop3. Apc001PE has no effect on aortic aneurysm and atherosclerotic development in ApoE-/- mice and hSOSTki.ApoE-/- mice with angiotensin II infusion. Apc001PE can promote bone formation in hSOSTki mice and ovariectomy-induced osteoporotic rats. In summary, sclerostin loop3 cannot participate in protecting the cardiovascular system, but participates in inhibiting bone formation.
Related Papers
- → Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation(2022)184 cited
- → Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review(2015)88 cited
- → A sclerostin-based theory for strain-induced bone formation(2010)27 cited
- Sclerostin, an osteocytes-derived bone-forming inhibitor.(2013)
- [Anti-sclerostin antibodies].(2011)